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2148bleeding risk using a validated PCI bleeding model from NCDR
(5). In method 2, we performed 1:1 matching of transradial and
transfemoral PCI patients based on propensity score accounting for
19 demographic, clinical, and procedural covariates including
anticoagulation strategy. In method 3, we performed adjustment
based on inverse probability treatment weights (IPTW) generated
from the propensity score model. Analyses were performed using
STATA version 11.2 (College Station, Texas).
A total of 17,509 patients underwent PCI, with 17.8%
of procedures performed via the transradial approach. A total of
240 (1.4%) patients had either access site bleeding (102 events) or
nonaccess site bleeding (144 events). Although there were statis-
tically signiﬁcant differences in 15 of 17 baseline characteristics
examined, patients undergoing transfemoral and transradial PCI
were balanced on all characteristics after using propensity score
methods (standardized differences <10% for all variables).
The results of the 3 different analyses are presented in Figure 1.
Statistically signiﬁcant reductions in access site bleeding were seen
with transradial PCI using all 3 methodologies. However, statis-
tically signiﬁcant reductions in nonaccess site bleeding were also
seen with transradial PCI with all 3 methodologies, suggesting
residual confounding.
In these analyses, we identiﬁed a relationship between transradial
PCI and nonaccess site bleeding that was not identiﬁed in
randomized clinical trials and that is most likely due to the inability
of our methods to fully adjust for unmeasured patient differences.
While it would be possible to adjust the results of the primary
hypothesis based on the magnitude of confounding of the falsiﬁca-
tion endpoint, we would not recommend this approach until the
validity of such methods has been further explored. These data
highlight the dangers of assuming that modern statistical methods
alone fully adjust for confounding in nonrandomized data. In
observational comparisons such as the comparison of transradial and
transfemoral PCI in which differences in unmeasured patient
characteristics are likely to be signiﬁcant based on treatment selec-
tion, the use of falsiﬁcation endpoints may be useful when available.Neil J. Wimmer, MD, MScy
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Cardiovasc Interv 2009;2:222–9.Letters to the EditorIs Ischemia Really Bad for You?We read with great interest the substudy of the Surgical Treatment
for Ischemic Heart Failure trial on inducible ischemia published
in the Journal alongside the accompanying editorial (1,2). This
fascinating report demonstrated that patients with inducible
myocardial ischemia and severe left ventricular systolic dysfunction
did not derive greater beneﬁt from coronary artery bypass grafting
compared with medical therapy. This fundamentally challenges
whether we should be revascularizing patients with left ventricular
systolic dysfunction on the basis of ischemia alone. Although
potentially practice changing, we believe that this is not necessarily
surprising, given that adverse events in patients with severe left
ventricular systolic dysfunction are more likely to relate to heart
failure rather than the underlying coronary atherosclerosis per se.
Indeed, this is also the likely explanation for the lack of beneﬁt
from statin therapy in this patient cohort (3,4).
The accompanying editorial goes on to ask the more wide
ranging question of whether ischemia is a legitimate target for
revascularization in any patient with coronary artery disease, irre-
spective of systolic function. We believe this is one of the most
fundamental questions facing cardiologists today. Early studies
established a clear association between increasing myocardial
ischemia and adverse events (5), leading to the assumption that
reducing ischemia, for instance with percutaneous coronary inter-
vention, would improve prognosis. However, percutaneous coro-
nary intervention has to date failed to demonstrate a consistent
reduction in myocardial infarction or mortality among patients with
stable disease, despite effectively reducing ischemia. Conversely,
statin therapy has profound effects on these outcomes, with rela-
tively little effect on the severity of coronary artery obstruction (6).
The question therefore arises whether ischemia is in itself bad for
you or whether it is in fact simply a surrogate for plaque burden.
Certainly plaque burden would better explain the results of the
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and the clear beneﬁt held by coronary artery bypass grafting
over percutaneous coronary intervention, a technique that not only
relieves ischemia but also protects against rupture in all the prox-
imal plaques, which it bypasses. To this end, the results of the
ISCHEMIA (International Study of Comparative Health Effec-
tiveness With Medical and Invasive Approaches) study are keenly
anticipated, although it will be important to assess whether any
beneﬁt relates directly to the reduction of the ischemic burden.*Nikhil V. Joshi, MD
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381:629–38.ReplyIs Ischemia Really Bad for You?
We appreciate the comments of Drs. Joshi and Dweck and agree
with them that our study challenges the concept that inducible
myocardial ischemia is a requisite for determining which patients
with coronary artery disease and left ventricular dysfunction will
beneﬁt from surgical revascularization (1). Although this may not
be surprising, it had never been proved in the context of
a prospective randomized clinical trial. A separate analysis revealed
that the most common mode of death in patients enrolled in the
STICH (Surgical Treatment for Ischemic Heart Failure) trial was
sudden death (2). We have postulated that the dissociation we
observed between myocardial ischemia and prognosis may indicate
that ischemia induced during stress is not causally related to eitherthe risk for plaque rupture or nonischemic ventricular arrhythmias
that may contribute to sudden death.
We also concur regarding the apparent disconnect between the
presence and extent of inducible ischemia during stress testing and
the lack of tangible beneﬁts delivered by therapies (such as percu-
taneous coronary intervention) to relieve ischemia in patients with
stable coronary artery disease. Although the results of our study
cannot be extrapolated to all patients with ischemic heart disease,
including those with normal left ventricular systolic function, they
do defy the long-believed paradigm linking reduction of ischemic
burden and improvement in prognosis.
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LVAD Ramp Test
We would like to add a letter to our paper previously published by
Uriel et al. (1).
We are honored to have been contacted by many centers
nationally and internationally about our ramp test. However, it has
come to our attention that some centers performing the test are
unfortunately having issues analyzing their collected data. To
ensure that such technical issues do not limit the applicability of
the ramp study in clinical decision making, we propose to add
a brief elaboration of our analysis in addition to a downloadable,
pre-formatted Excel spreadsheet.
As we know, left ventricular end-diastolic diameter (LVEDD),
power, and pulsatility index (PI) are expected to change with the
manipulation of a patient’s left ventricular assist device (LVAD)
speed in a well-functioning pump. For our ramp protocol, we start
at 8,000 RPM and increase the LVAD speed by 400-RPM
increments. For our linear ﬁt analysis, each 400-RPM increment
is given a value of 1 “speed change.” Therefore, the values of the
dependent variables (LVEDD, power, and PI) are plotted against
the number of 400-RPM speed changes (i.e., 8,000 ¼ 0; 8,400 ¼
1; 8,800 ¼ 2, and so on). A numerical slope can then be generated
via the Excel function: ¼ slope (dependent variable, number of
speed changes) as seen in Figure 1. For this example, the LVEDD
slope ¼ 0.149.
